EVALUATION OF HEPATITIS C TREATMENT OUTCOME AMONG PEOPLE WHO INJECT DRUGS IN GEORGIA NeoLab

Kamkamidze G¹<u>,</u>Butsashvili M¹, Gulbiani L¹<u>,</u> Kamkamidze T¹, Kochlamazashvili M¹, Kajaia M¹


¹Health Research Union

Background:

HU

The prevalence of HCV antibodies in Georgia is very high (7.7%). People who inject drugs (PWID) account for the largest group of infected patients in Georgia. In 2015, the Ministry of Health in collaboration with the US Centers for Disease Control and Prevention (CDC) implemented an HCV elimination program. There were initial concerns among medical personnel and policy makers that PWID would have poor treatment compliance that would lead to poorer outcomes. This study was designed to estimate rapid virologic response (RVR) and sustained viral response (SVR) rates among PWID compared to those without a history of injection drug use (non-PWID).

SVR rates among PWIDs and Non-PWIDs



Results

Of the 4091 patients in the HCV elimination program, 1775 (43.4%) had history of injecting drugs. The two study groups were comparable in age. Among PWID only 0.7% were females compared to 27.1% of females among non-PWID (p<0.0001). Genotype 3 predominated among PWID (43.2%) vs. non-PWID (34.8%, p<0.001). RVR was higher in PWID (97.3%) vs non-PWID (95.0%, p<0.01). For PWID compared to non-PWID, SVR rates were comparable (96.0% vs 95.0%, p=0.24) as were advanced liver fibrosis (44.5% vs 43.1%, p=0.44).

Conclusions

Treatment outcomes among PWID were similar to non-PWID, suggesting that treatment adherence may be sufficiently similar to achieve reasonably comparable clinical outcomes.

Methos

Sociodemographic, behavioral and clinical data were extracted from one of the largest participating clinics, NeoLab. Advanced liver fibrosis was defined as FIB4 >3.25 and liver elastography >=F3. RVR was measured at week 4 after treatment initiation and SVR was measured at 12-24 weeks after completion (SVR). Sociodemographic, clinical and laboratory data were compared for PWID and non-PWID.

Contact:

Maia Butsashvili Health Research Union/Clinic NeoLab Email: maiabutsashvili@gmail.com Website:neolab.ge/hru.ge Phone:+995 591 706 799

Acknowledgements

The study was funded by Shota Rustaveli National Science Foundation grant # FR17_371